Astal Laboratories Limited has announced a substantial share acquisition by Kommera Harish, a non-promoter investor, under SEBI's substantial acquisition regulations. The transaction, completed on January 14, 2026, involved the allotment of 26,98,140 equity shares through preferential allotment pursuant to a share swap arrangement.

Transaction Details

The share acquisition significantly increased Harish's stake in the pharmaceutical company. The transaction details are presented below:

Acquisition Structure

The acquisition was executed through preferential allotment mechanism as part of a share swap transaction. Harish acquired 26,98,140 equity shares, representing 6.39% of the company's total share capital and 6.13% of diluted share capital. The investor belongs to the non-promoter group and had no encumbered shares or convertible securities before or after the transaction.

Company Capital Structure Changes

The transaction resulted in significant changes to Astal Laboratories' capital structure:

All shares carry a face value of ₹10.00 each. The substantial increase in share capital indicates a significant corporate restructuring through the share swap mechanism.

Regulatory Compliance

The disclosure was made pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Company Secretary Mahendra Kumar submitted the required documentation to BSE Limited on January 19, 2026. The company's shares are listed on BSE Limited under scrip code 512600 and security ID ASTALLTD.

Astal Laboratories Limited, formerly known as Macro International Limited, operates from its registered office in Noida, Uttar Pradesh, with corporate office located in Hyderabad, Telangana. The transaction represents a significant development in the company's shareholding pattern and demonstrates investor confidence in the pharmaceutical company's prospects.

Astal Laboratories Limited has completed a significant preferential share allotment to non-promoter investors, strengthening its equity base through strategic allocation of 17.50 lakh shares on January 14, 2026.

Share Allotment Details

The company allotted shares to two non-promoter investors through different mechanisms:

Shareholding Pattern Changes

The allotment significantly altered the shareholding structure of both investors:

Before Acquisition

After Acquisition

Capital Structure Impact

The preferential allotment resulted in substantial changes to the company's equity capital:

Regulatory Compliance

The transaction was conducted in full compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Vupparapalli Chandra Sekhar Reddy filed the required disclosure under Regulation 29(2) on behalf of both investors on January 15, 2026. The disclosure was submitted to BSE Limited, where the company's shares are listed under scrip code 512600.

Transaction Structure

The allotment involved two primary mechanisms - conversion of existing warrants into equity shares and preferential issue through share swap arrangements. The warrant conversions totaled 5.00 lakh shares (2.50 lakh each for both investors), while the share swap arrangement contributed 12.50 lakh additional shares to Vupparapalli Pavani's holdings. This strategic allocation demonstrates the company's approach to strengthening its equity base through targeted investor participation.